Avedro, Inc. marked the one year anniversary of the U.S. commercial availability of Photrexa Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa (riboflavin 5’-phosphate ophthalmic solution), the drugs used in corneal cross-linking with the KXL System, for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. In that period, Avedro estimates that 10,000 procedures have been completed at more than 250 sites. Avedro also reported significant progress in its efforts to secure insurance coverage of its cross-linking procedure, supported by the recent launch of the ARCH Program (Avedro Reimbursement Customer Hub) to expand commercial coverage and to assist with the commercial payer appeals process. Thus far in 2017, insurance coverage for the FDA-approved cross-linking treatment has grown from three carriers to more than twenty-five, demonstrating an encouraging trend in coverage. These commercial carriers cover approximately 85 million insured Americans. Avedro continues to make a significant investment in the next generation of cross-linking procedures and technologies that will protect and improve vision. Presently, the company is finalizing plans for a U.S. Phase 3 epi-on cross-linking study for the treatment of progressive keratoconus. In addition, there are several clinical development programs active in Europe that will further the study of non-invasive treatments.